b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31347950</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>14</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>22</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1527-3792</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>202</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The Journal of urology</Title>\n                <ISOAbbreviation>J. Urol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1120-1126</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1097/JU.0000000000000460</ELocationID>\n            <Abstract>\n                <AbstractText Label="PURPOSE">Cryoablation is done in select patients with pT1b nonmetastatic renal cell carcinoma without convincing proof of efficacy. Our aim was to test for differences in the cancer specific mortality rate for cryoablation and partial nephrectomy in T1b nonmetastatic renal cell carcinoma cases.</AbstractText>\n                <AbstractText Label="MATERIALS AND METHODS">In the 2004 to 2015 SEER (Surveillance, Epidemiology, and End Results) database we identified 5,763 patients with a T1b tumor treated with cryoablation or partial nephrectomy. Modeling relied on multivariable logistic regression models predicting cryoablation vs partial nephrectomy. After 1:2 ratio propensity score matching between patients treated with cryoablation vs partial nephrectomy we used cumulative incidence plot and competing risks regression to test differences in cancer specific mortality and other cause mortality rates.</AbstractText>\n                <AbstractText Label="RESULTS">Relative to the 5,521 patients who underwent partial nephrectomy the 242 treated with cryoablation were older, had smaller tumors and more frequently harbored unclassified renal cell carcinoma of low or unknown grade. Median followup was 38 months. In multivariable logistic regression models predicting cryoablation vs partial nephrectomy more advanced patient age was an independent predictor (OR 1.03; p=0.007). After propensity score matching and other cause mortality adjustment the 5-year cancer specific mortality rate was 2.5-fold higher after cryoablation than after partial nephrectomy (p=0.03). Conversely after propensity score matching and cancer specific mortality adjustment the 5-year other cause mortality rate was similar to that of partial nephrectomy after cryoablation (HR 1.45, p=0.12). The major limitation of this study was the lack of recurrence and metastatic progression data.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">The current findings demonstrated a 2.5-fold increase in cancer specific mortality when cryoablation was performed in patients with pT1b renal cell carcinoma. This observation should be interpreted as a contraindication to cryoablation outside clinical trials or institutional protocols.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y" EqualContrib="Y">\n                    <LastName>Pecoraro</LastName>\n                    <ForeName>Angela</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y" EqualContrib="Y">\n                    <LastName>Palumbo</LastName>\n                    <ForeName>Carlotta</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Knipper</LastName>\n                    <ForeName>Sophie</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mistretta</LastName>\n                    <ForeName>Francesco A</ForeName>\n                    <Initials>FA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, European Institute of Oncology, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tian</LastName>\n                    <ForeName>Zhe</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shariat</LastName>\n                    <ForeName>Shahrokh F</ForeName>\n                    <Initials>SF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, Medical University of Vienna, Vienna, Austria.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Saad</LastName>\n                    <ForeName>Fred</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Briganti</LastName>\n                    <ForeName>Alberto</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fiori</LastName>\n                    <ForeName>Cristian</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Porpiglia</LastName>\n                    <ForeName>Francesco</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Karakiewicz</LastName>\n                    <ForeName>Pierre I</ForeName>\n                    <Initials>PI</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Quebec, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>26</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Urol</MedlineTA>\n            <NlmUniqueID>0376374</NlmUniqueID>\n            <ISSNLinking>0022-5347</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>AIM</CitationSubset>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>J Urol. 2019 Dec;202(6):1125</RefSource>\n                <PMID Version="1">31460825</PMID>\n            </CommentsCorrections>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>J Urol. 2019 Dec;202(6):1125-1126</RefSource>\n                <PMID Version="1">31460826</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>\n                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003452" MajorTopicYN="N">Cryosurgery</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>\n                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009392" MajorTopicYN="N">Nephrectomy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">carcinoma</Keyword>\n            <Keyword MajorTopicYN="Y">cryosurgery</Keyword>\n            <Keyword MajorTopicYN="Y">kidney</Keyword>\n            <Keyword MajorTopicYN="Y">mortality</Keyword>\n            <Keyword MajorTopicYN="Y">nephrectomy</Keyword>\n            <Keyword MajorTopicYN="Y">renal cell</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31347950</ArticleId>\n            <ArticleId IdType="doi">10.1097/JU.0000000000000460</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'